Rare side effects include gallbladder disease, pancreatitis, acute kidney injury (typically related to hypovolemia), hypersensitivity reactions, and gastroparesis [12,41]
Retatrutide does not yet have dedicated cardiovascular or renal outcome trials, though Phase 3 studies evaluating these endpoints are currently enrolling participants with expected completion in 2026
health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisks Wegovy and Eli Lillys Zepbound
Semaglutide acts on the brains appetite control centers, helping to reduce hunger and promote a feeling of fullness
Most patients reach a maintenance dose between 1.0 and 2.4 mcg weekly, though individual variation is significant and influenced by genetics, weight baseline, and metabolic health